Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Buhl, S, Dorn-Rasmussen, M, Brynskov, J, Ainsworth, MA, Bendtzen, K, Klausen, PH, Bolstad, N, Warren, DJ & Steenholdt, C 2020, 'Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease', Scandinavian Journal of Gastroenterology, bind 55, nr. 8, s. 884-890. https://doi.org/10.1080/00365521.2020.1786852

APA

Buhl, S., Dorn-Rasmussen, M., Brynskov, J., Ainsworth, M. A., Bendtzen, K., Klausen, P. H., Bolstad, N., Warren, D. J., & Steenholdt, C. (2020). Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 55(8), 884-890. https://doi.org/10.1080/00365521.2020.1786852

CBE

MLA

Vancouver

Author

Buhl, Sine ; Dorn-Rasmussen, Maria ; Brynskov, Jørn ; Ainsworth, Mark A ; Bendtzen, Klaus ; Klausen, Pia Helene ; Bolstad, Nils ; Warren, David J ; Steenholdt, Casper. / Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease. I: Scandinavian Journal of Gastroenterology. 2020 ; Bind 55, Nr. 8. s. 884-890.

Bibtex

@article{fb838680445346a49952bc30bea20467,
title = "Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease",
abstract = "BACKGROUND: Primary non-response to infliximab (IFX) inherits a poor prognosis in inflammatory bowel disease (IBD). We explored underlying mechanisms and therapeutic thresholds in an effort to provide basis for optimizing therapy.METHODS: A prospectively followed cohort of 166 IBD patients having received standard IFX induction therapy (5 mg/kg at weeks 2, 6, and 14) had trough IFX and anti-IFX antibodies (Abs) retrospectively assessed at weeks 2 (n = 148) and 6 (n = 108). Circulating TNFα was measured in matched primary non-responders (n = 29) and responders (n = 21) at baseline and weeks 6 and 14. Clinical outcome at week 14 was supported by disease activity scores in half of patients.RESULTS: In all, 18 patients (11%) had primary non-response. Infliximab was consistently lower throughout the induction phase in non-responders as compared to responders (Week 2: IFX median 18.9 μg/mL vs. 23.3, p < .05. Week 6: 8.4 vs. 17.0, p < .05). Optimal IFX thresholds associated with response was 22.9 μg/mL at week 2 (sensitivity 51%, specificity 80%, AUCROC 0.67, p < .05) and 11.8 at week 6 (72%, 77%, 0.71, p < .05). Anti-IFX Abs occurred in 28% of primary non-responders and associated with low IFX and treatment failure (OR 13.7 [2.8-67.5], p < .01). Markers of disease activity (disease activity scores, albumin, CRP) also associated with low IFX. Circulating TNFα was higher throughout induction in non-responders with ulcerative colitis but not Crohn's disease.CONCLUSION: IBD patients with primary IFX failure generally have lower IFX trough than responders during early induction phase. Pharmacokinetic failure seems common in ulcerative colits, whereas pharmacodynamic failure appears common in Crohn's disease.",
keywords = "Infliximab, primary non-response, pharmacokinetics, pharmacodynamics, therapeutic thresholds, anti-IFX Abs, TNF-alpha",
author = "Sine Buhl and Maria Dorn-Rasmussen and J{\o}rn Brynskov and Ainsworth, {Mark A} and Klaus Bendtzen and Klausen, {Pia Helene} and Nils Bolstad and Warren, {David J} and Casper Steenholdt",
year = "2020",
month = aug,
doi = "10.1080/00365521.2020.1786852",
language = "English",
volume = "55",
pages = "884--890",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Taylor & Francis",
number = "8",

}

RIS

TY - JOUR

T1 - Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease

AU - Buhl, Sine

AU - Dorn-Rasmussen, Maria

AU - Brynskov, Jørn

AU - Ainsworth, Mark A

AU - Bendtzen, Klaus

AU - Klausen, Pia Helene

AU - Bolstad, Nils

AU - Warren, David J

AU - Steenholdt, Casper

PY - 2020/8

Y1 - 2020/8

N2 - BACKGROUND: Primary non-response to infliximab (IFX) inherits a poor prognosis in inflammatory bowel disease (IBD). We explored underlying mechanisms and therapeutic thresholds in an effort to provide basis for optimizing therapy.METHODS: A prospectively followed cohort of 166 IBD patients having received standard IFX induction therapy (5 mg/kg at weeks 2, 6, and 14) had trough IFX and anti-IFX antibodies (Abs) retrospectively assessed at weeks 2 (n = 148) and 6 (n = 108). Circulating TNFα was measured in matched primary non-responders (n = 29) and responders (n = 21) at baseline and weeks 6 and 14. Clinical outcome at week 14 was supported by disease activity scores in half of patients.RESULTS: In all, 18 patients (11%) had primary non-response. Infliximab was consistently lower throughout the induction phase in non-responders as compared to responders (Week 2: IFX median 18.9 μg/mL vs. 23.3, p < .05. Week 6: 8.4 vs. 17.0, p < .05). Optimal IFX thresholds associated with response was 22.9 μg/mL at week 2 (sensitivity 51%, specificity 80%, AUCROC 0.67, p < .05) and 11.8 at week 6 (72%, 77%, 0.71, p < .05). Anti-IFX Abs occurred in 28% of primary non-responders and associated with low IFX and treatment failure (OR 13.7 [2.8-67.5], p < .01). Markers of disease activity (disease activity scores, albumin, CRP) also associated with low IFX. Circulating TNFα was higher throughout induction in non-responders with ulcerative colitis but not Crohn's disease.CONCLUSION: IBD patients with primary IFX failure generally have lower IFX trough than responders during early induction phase. Pharmacokinetic failure seems common in ulcerative colits, whereas pharmacodynamic failure appears common in Crohn's disease.

AB - BACKGROUND: Primary non-response to infliximab (IFX) inherits a poor prognosis in inflammatory bowel disease (IBD). We explored underlying mechanisms and therapeutic thresholds in an effort to provide basis for optimizing therapy.METHODS: A prospectively followed cohort of 166 IBD patients having received standard IFX induction therapy (5 mg/kg at weeks 2, 6, and 14) had trough IFX and anti-IFX antibodies (Abs) retrospectively assessed at weeks 2 (n = 148) and 6 (n = 108). Circulating TNFα was measured in matched primary non-responders (n = 29) and responders (n = 21) at baseline and weeks 6 and 14. Clinical outcome at week 14 was supported by disease activity scores in half of patients.RESULTS: In all, 18 patients (11%) had primary non-response. Infliximab was consistently lower throughout the induction phase in non-responders as compared to responders (Week 2: IFX median 18.9 μg/mL vs. 23.3, p < .05. Week 6: 8.4 vs. 17.0, p < .05). Optimal IFX thresholds associated with response was 22.9 μg/mL at week 2 (sensitivity 51%, specificity 80%, AUCROC 0.67, p < .05) and 11.8 at week 6 (72%, 77%, 0.71, p < .05). Anti-IFX Abs occurred in 28% of primary non-responders and associated with low IFX and treatment failure (OR 13.7 [2.8-67.5], p < .01). Markers of disease activity (disease activity scores, albumin, CRP) also associated with low IFX. Circulating TNFα was higher throughout induction in non-responders with ulcerative colitis but not Crohn's disease.CONCLUSION: IBD patients with primary IFX failure generally have lower IFX trough than responders during early induction phase. Pharmacokinetic failure seems common in ulcerative colits, whereas pharmacodynamic failure appears common in Crohn's disease.

KW - Infliximab

KW - primary non-response

KW - pharmacokinetics

KW - pharmacodynamics

KW - therapeutic thresholds

KW - anti-IFX Abs

KW - TNF-alpha

U2 - 10.1080/00365521.2020.1786852

DO - 10.1080/00365521.2020.1786852

M3 - Journal article

C2 - 32631131

VL - 55

SP - 884

EP - 890

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 8

ER -

ID: 61864864